Publications

Goldberg JS, Vargas M, Rosmarin AS, Milowsky MI, Papanicoloau N, Gudas LJ, Shelton G, Feit K, Petrylak D, Nanus DM.  2002.  Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.. Cancer. 95(6):1220-7.

Zhan HChun, Gudas LJ, Bok D, Rando R, Nanus DM, Tickoo SK.  2003.  Differential expression of the enzyme that esterifies retinol, lecithin:retinol acyltransferase, in subtypes of human renal cancer and normal kidney.. Clin Cancer Res. 9(13):4897-905.

Boorjian S, Tickoo SK, Mongan NP, Yu H, Bok D, Rando RR, Nanus DM, Scherr DS, Gudas LJ.  2004.  Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer.. Clin Cancer Res. 10(10):3429-37.

Li R, Faria TN, Boehm M, Nabel EG, Gudas LJ.  2004.  Retinoic acid causes cell growth arrest and an increase in p27 in F9 wild type but not in F9 retinoic acid receptor beta2 knockout cells.. Exp Cell Res. 294(1):290-300.

Touma SEllen, Goldberg JS, Moench P, Guo X, Tickoo SK, Gudas LJ, Nanus DM.  2005.  Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.. Clin Cancer Res. 11(9):3558-66.

Boorjian S, Scherr DS, Mongan NP, Zhuang Y, Nanus DM, Gudas LJ.  2005.  Retinoid receptor mRNA expression profiles in human bladder cancer specimens.. Int J Oncol. 26(4):1041-8.

Raman JD, Mongan NP, Liu L, Tickoo SK, Nanus DM, Scherr DS, Gudas LJ.  2006.  Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma.. Carcinogenesis. 27(3):499-507.

Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MVallee, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ et al..  2007.  Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.. J Immunother. 30(6):655-62.

Tavares TS, Nanus D, Yang XJ, Gudas LJ.  2008.  Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment.. Cancer Biol Ther. 7(10):1607-18.

David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM.  2010.  Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies.. Cancer Biol Ther. 9(9):678-84.

Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ.  2011.  Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α.. Cancer Res. 71(21):6848-56.

Marcinkiewicz K, Scotland KB, Boorjian SA, Nilsson EM, Persson JLiao, Abrahamsson PAnders, Allegrucci C, Hughes IA, Gudas LJ, Mongan NP.  2012.  The androgen receptor and stem cell pathways in prostate and bladder cancers (review).. Int J Oncol. 40(1):5-12.

Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ.  2013.  Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis.. Cancer Res. 73(9):2916-25.

Kashyap V, Ahmad S, Nilsson EM, Helczynski L, Kenna S, Persson JLiao, Gudas LJ, Mongan NP.  2013.  The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.. Mol Oncol. 7(3):555-66.

Laursen KB, Mongan NP, Zhuang Y, Ng MM, Benoit YD, Gudas LJ.  2013.  Polycomb recruitment attenuates retinoic acid-induced transcription of the bivalent NR2F1 gene.. Nucleic Acids Res. 41(13):6430-43.

Gudas LJ, Fu L, Minton DR, Mongan NP, Nanus DM.  2014.  The role of HIF1α in renal cell carcinoma tumorigenesis.. J Mol Med (Berl). 92(8):825-36.

Minton DR, Fu L, Chen Q, Robinson BD, Gross SS, Nanus DM, Gudas LJ.  2015.  Analyses of the transcriptome and metabolome demonstrate that HIF1α mediates altered tumor metabolism in clear cell renal cell carcinoma.. PLoS One. 10(4):e0120649.

Fu L, Minton DR, Zhang T, Nanus DM, Gudas LJ.  2015.  Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome.. Mol Cancer Res. 13(5):870-8.

Orfali N, O'Donovan TR, Nyhan MJ, Britschgi A, Tschan MP, Cahill MR, Mongan NP, Gudas LJ, McKenna SL.  2015.  Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation.. Exp Hematol. 43(9):781-93.e2.

Williams RM, Shah J, Ng BD, Minton DR, Gudas LJ, Park CY, Heller DA.  2015.  Mesoscale nanoparticles selectively target the renal proximal tubule epithelium.. Nano Lett. 15(4):2358-64.

Nilsson EM, Laursen KB, Whitchurch J, McWilliam A, Ødum N, Persson JL, Heery DM, Gudas LJ, Mongan NP.  2015.  MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators.. Oncotarget. 6(34):35710-25.

Simandi Z, Horvath A, Wright LC, Cuaranta-Monroy I, De Luca I, Karolyi K, Sauer S, Deleuze J-F, Gudas LJ, Cowley SM et al..  2016.  OCT4 Acts as an Integrator of Pluripotency and Signal-Induced Differentiation.. Mol Cell. 63(4):647-661.

Minton DR, Fu L, Mongan NP, Shevchuk MM, Nanus DM, Gudas LJ.  2016.  Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma.. Clin Cancer Res. 22(11):2791-801.

Nanus DM, Gudas LJ.  2016.  The Tale of Two Hypoxia-Inducible Factors in Renal Cell Carcinoma.. Eur Urol. 69(4):658-659.

van der Mijn JC, Awamlh BAl Hussein, Khan AIslam, Posada-Calderon L, Oromendia C, Fainberg J, Alshak M, Elahjji R, Pierce H, Taylor B et al..  2019.  Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series.. PLoS One. 14(12):e0226285.